micafungin na for i.v. infusion 50mg "meiji" (ミカファンギンna点滴静注用50mg「明治」)
meiji seika pharma co., ltd. - micafungin sodium - injection
micafungin na for i.v. infusion 75mg "meiji" (ミカファンギンna点滴静注用75mg「明治」)
meiji seika pharma co., ltd. - micafungin sodium - injection
micafungin sodium i.v. drip infusion 25 mg "nichiiko" (ミカファンギンナトリウム点滴静注用25mg「日医工」)
nichi-iko pharmaceutical co.,ltd - micafungin sodium - injection
micafungin sodium i.v. drip infusion 50 mg "nichiiko" (ミカファンギンナトリウム点滴静注用50mg「日医工」)
nichi-iko pharmaceutical co.,ltd - micafungin sodium - injection
micafungin sodium i.v. drip infusion 75 mg "nichiiko" (ミカファンギンナトリウム点滴静注用75mg「日医工」)
nichi-iko pharmaceutical co.,ltd - micafungin sodium - injection
funzoren 50 mg powder for concentrate for solution for infusion
vocate pharmaceuticals s.a 150, gounari str, 166 74 glyfada, athens, greece - micafungin sodium - powder for concentrate for solution for infusion - micafungin sodium 10 mg/ml - antimycotics for systemic use
funzoren 100 mg powder for concentrate for solution for infusion
vocate pharmaceuticals s.a 150, gounari str, 166 74 glyfada, athens, greece - micafungin sodium - powder for concentrate for solution for infusion - micafungin sodium 20 mg/ml - antimycotics for systemic use
mycamine 100 powder for solution for infusion
astellas pharma (pty) ltd 5 osborne lane, bedfordview south africa - micafungin - powder for solution for infusion - 100 mg micafungin powder for solution for - micafungin
mycamine 50 powder for solution for infusion
astellas pharma (pty) ltd 5 osborne lane, bedfordview south africa - micafungin - powder for solution for infusion - 50 mg micafungin powder for solution for - micafungin
mycamine
astellas pharma europe b.v. - micafungin - candidiasis - antimycotics for systemic use - mycamine is indicated for:adults, adolescents ≥ 16 years of age and elderlytreatment of invasive candidiasis;treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate;prophylaxis of candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.children (including neonates) and adolescents < 16 years of agetreatment of invasive candidiasis.prophylaxis of candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.the decision to use mycamine should take into account a potential risk for the development of liver tumours. mycamine should therefore only be used if other antifungals are not appropriate.